methyl 5-[{3-[(3-{[6-(1-tert-butoxy-2-methyl-1-oxopropan-2-yl)pyridin-3-yl]carbamoyl}-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)carbamoyl]benzyl}(pentan-3-yl)amino]-2,2-dimethyl-5-oxopentanoate | 1432130-52-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 5-[{3-[(3-{[6-(1-tert-butoxy-2-methyl-1-oxopropan-2-yl)pyridin-3-yl]carbamoyl}-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)carbamoyl]benzyl}(pentan-3-yl)amino]-2,2-dimethyl-5-oxopentanoate
• 英文别名: Methyl 5-[{3-[(3-{[6-(1-tert-butoxy-2-methyl-1-oxopropan-2-yl)pyridin-3-yl]carbamoyl}-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)carbamoyl]benzyl}(pentan-3-yl)amino]-2,2-dimethyl-5-oxopentanoate；methyl 2,2-dimethyl-5-[[3-[[3-[[6-[2-methyl-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]pyridin-3-yl]carbamoyl]-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl]phenyl]methyl-pentan-3-ylamino]-5-oxopentanoate
• CAS: 1432130-52-3
• 化学式: C₄₃H₅₈N₄O₇S
• 分子量: 775.022
• InChiKey: JOCKQGNQJCVNIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  55
• 可旋转键数：
  18
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  172
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  methyl 5-[{3-[(3-{[6-(1-tert-butoxy-2-methyl-1-oxopropan-2-yl)pyridin-3-yl]carbamoyl}-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)carbamoyl]benzyl}(pentan-3-yl)amino]-2,2-dimethyl-5-oxopentanoate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 15.0h， 以550 mg的产率得到2-{5-[({2-[(3-{[(5-methoxy-4,4-dimethyl-5-oxopentanoyl)(pentan-3-yl)amino]methyl}benzoyl)amino]-4,5,6,7-tetrahydro-1-benzothiophen-3-yl}carbonyl)amino]pyridin-2-yl}-2-methylpropanoic acid
  参考文献：
  名称：

  AMINOALKYL-SUBSTITUTED N-THIENYL BENZAMIDE DERIVATIVE

  摘要：

  公开号：

  EP2772490B1

文献信息

• Aminoalkyl-substituted N-thienylbenzamide derivative
  申请人：ASTELLAS PHARMA INC.

  公开号：US09062032B2

  公开（公告）日：2015-06-23

  [Problem] To provide a compound that has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. [Means for Solution] The present inventors conducted their studies on a compound that has an NPT-IIb inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. As a result, they created an aminoalkyl-substituted N-thienylbenzamide derivative which has NPT-IIb inhibitory action, thereby completing the present invention. The aminoalkyl-substituted N-thienylbenzamide derivative of the present invention has an NPT-IIb inhibitory action and can be used as an agent for preventing and/or treating hyperphosphatemia.

  [问题] 提供一种具有肠道磷酸转运体（NPT-IIb）抑制作用并可用作治疗和/或预防高磷血症药物的有效成分的化合物。 [解决方法] 现有发明人对具有NPT-IIb抑制作用并可用作治疗和/或预防高磷血症药物的有效成分的化合物进行了研究。结果，他们创造了一种具有NPT-IIb抑制作用的氨基烷基取代N-噻吩基苯甲酰胺衍生物，从而完成了本发明。本发明的氨基烷基取代N-噻吩基苯甲酰胺衍生物具有NPT-IIb抑制作用，并可用作预防和/或治疗高磷血症的药物。
• AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE
  申请人：ASTELLAS PHARMA INC.

  公开号：US20150031727A1

  公开（公告）日：2015-01-29

  [Problem] To provide a compound that has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. [Means for Solution] The present inventors conducted their studies on a compound that has an NPT-IIb inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. As a result, they created an aminoalkyl-substituted N-thienylbenzamide derivative which has NPT-IIb inhibitory action, thereby completing the present invention. The aminoalkyl-substituted N-thienylbenzamide derivative of the present invention has an NPT-IIb inhibitory action and can be used as an agent for preventing and/or treating hyperphosphatemia.

  【问题】提供一种具有肠道磷酸转运体（NPT-IIb）抑制作用并且可用作治疗和/或预防高磷血症药物的活性成分的化合物。【解决方案】本发明人对一种具有NPT-IIb抑制作用并且可用作治疗和/或预防高磷血症药物的活性成分的化合物进行了研究。结果，他们创造了一种具有NPT-IIb抑制作用的氨基烷基取代的N-噻吩基苯酰胺衍生物，从而完成了本发明。本发明的氨基烷基取代的N-噻吩基苯酰胺衍生物具有NPT-IIb抑制作用，并可用作预防和/或治疗高磷血症的药物。
• US9062032B2
  申请人：——

  公开号：US9062032B2

  公开（公告）日：2015-06-23
• AMINOALKYL-SUBSTITUTED N-THIENYL BENZAMIDE DERIVATIVE
  申请人：Astellas Pharma Inc.

  公开号：EP2772490B1

  公开（公告）日：2016-04-06